Executive readout · one minute
Call research workspace
Read the call alongside every captured source. Audio, transcript, slides and SEC filings stay in one workspace.
RPRX
$58.60
+0.07%
RPRX · Royalty Pharma plc
$58.60
+0.04 (+0.07%)
At close · Aug 14
Market Cap
$33.70B
Shares
575.00M
All earnings calls
Earnings call · FY2026 Q2
Royalty Pharma Q2 2026 Financial Results Call
Royalty Pharma Q2 2026 Financial Results Call
Forward guidance
4 guided metrics
Management's latest ranges and targets are included below.
Research coverage
3 live sources
Switch sources without leaving this page or losing your listening position.
Revenue
$674.14M
+16.5% YoY
Diluted EPS
$0.04
-42.9% YoY
Net income
$17.88M
-44.4% YoY
Research materials
Open the source you need; every reader stays inside this workspace.
Forward guidance
From the 8-K filed Aug 5, 2026.
| Metric | Period | Guided | Basis |
|---|---|---|---|
|
Portfolio Receipts
table
full year 2026
|
$3.4B – $3.5B | — | |
|
Interest paid
table
full year 2026
|
$350M – $360M | — | |
|
Payments for operating and professional costs
table
full year 2026
|
5.5% – 6.5% | — | |
|
Interest paid
third quarter of 2026
|
$175M | — |
Quarter detail
How the reported period landed and where the business moved.
Company presentation
Slides
13 pages · use arrow keys or swipe to navigate
SEC filing · Item 2.02
8-K earnings release
Filed Aug 5, 2026 · complete as-filed document
SEC periodic report
10-Q report
Filed Aug 5, 2026 · complete as-filed document